Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short vs Long-term ADT with Salvage Radiotherapy in Prostate Cancer
NCT05781217Phase 3Recruiting
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triptorelin, goserelin and leuprolide in prostate cancer (PCa) (2 arms). Primary endpoint: Metastasis-free Survival at 5 years. Started Mar 2023; status: recruiting.
02
Drugs
triptorelingoserelinleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05781217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781217.